- Home
- DXCM vs INSM Comparison
DXCM vs INSM Comparison
Compare DXCM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | INSM |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1B | 23.0B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DXCM | INSM |
|---|---|---|
| Price | $70.27 | $103.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 24 |
| Target Price | $85.33 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 5.0M | 4.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.18 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.46 | $182.31 |
| Revenue Next Year | $12.31 | $65.19 |
| P/E Ratio | $134.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.11 | $90.39 |
| 52 Week High | $89.07 | $212.75 |
Technical Indicators
Market Signals| Indicator | DXCM | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 49.86 |
| Support Level | $62.86 | $98.90 |
| Resistance Level | $74.08 | $166.81 |
| Average True Range (ATR) | 2.66 | 5.20 |
| MACD | -0.99 | 2.12 |
| Stochastic Oscillator | 9.78 | 80.06 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.